X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with FDC LTD. - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs FDC LTD. - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA FDC LTD. AJANTA PHARMA/
FDC LTD.
 
P/E (TTM) x 20.9 17.5 119.8% View Chart
P/BV x 9.1 3.6 248.4% View Chart
Dividend Yield % 0.7 1.3 51.1%  

Financials

 AJANTA PHARMA   FDC LTD.
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
FDC LTD.
Mar-14
AJANTA PHARMA/
FDC LTD.
5-Yr Chart
Click to enlarge
High Rs1,720144 1,198.6%   
Low Rs1,10379 1,396.2%   
Sales per share (Unadj.) Rs194.647.6 409.1%  
Earnings per share (Unadj.) Rs45.27.6 594.3%  
Cash flow per share (Unadj.) Rs50.39.0 558.2%  
Dividends per share (Unadj.) Rs8.002.25 355.6%  
Dividend yield (eoy) %0.62.0 28.0%  
Book value per share (Unadj.) Rs132.047.5 277.8%  
Shares outstanding (eoy) m88.77177.83 49.9%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x7.32.3 310.1%   
Avg P/E ratio x31.214.6 213.5%  
P/CF ratio (eoy) x28.112.3 227.3%  
Price / Book Value ratio x10.72.3 456.8%  
Dividend payout %17.729.6 59.8%   
Avg Mkt Cap Rs m125,29919,784 633.3%   
No. of employees `000NANA-   
Total wages/salary Rs m2,5701,221 210.6%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m17,2758,459 204.2%  
Other income Rs m166394 42.3%   
Total revenues Rs m17,4428,852 197.0%   
Gross profit Rs m5,8072,070 280.5%  
Depreciation Rs m451249 180.9%   
Interest Rs m4931 157.7%   
Profit before tax Rs m5,4742,184 250.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-225 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,460606 241.1%   
Profit after tax Rs m4,0141,353 296.6%  
Gross profit margin %33.624.5 137.4%  
Effective tax rate %26.727.7 96.2%   
Net profit margin %23.216.0 145.2%  
BALANCE SHEET DATA
Current assets Rs m7,6394,355 175.4%   
Current liabilities Rs m2,7151,792 151.5%   
Net working cap to sales %28.530.3 94.1%  
Current ratio x2.82.4 115.8%  
Inventory Days Days4344 97.3%  
Debtors Days Days7925 319.0%  
Net fixed assets Rs m6,9143,025 228.6%   
Share capital Rs m177179 99.0%   
"Free" reserves Rs m11,4428,243 138.8%   
Net worth Rs m11,7218,453 138.7%   
Long term debt Rs m14911 1,389.7%   
Total assets Rs m14,81410,557 140.3%  
Interest coverage x112.971.4 158.1%   
Debt to equity ratio x00 1,002.3%  
Sales to assets ratio x1.20.8 145.5%   
Return on assets %27.413.1 209.2%  
Return on equity %34.216.0 213.9%  
Return on capital %46.523.5 197.9%  
Exports to sales %55.113.3 414.4%   
Imports to sales %6.03.3 179.6%   
Exports (fob) Rs m9,5271,126 846.3%   
Imports (cif) Rs m1,038283 366.9%   
Fx inflow Rs m10,4221,146 909.3%   
Fx outflow Rs m1,678355 472.3%   
Net fx Rs m8,744791 1,105.7%   
CASH FLOW
From Operations Rs m3,2641,485 219.8%  
From Investments Rs m-2,093-620 337.8%  
From Financial Activity Rs m-1,186-753 157.6%  
Net Cashflow Rs m-15113 -13.1%  

Share Holding

Indian Promoters % 73.8 68.9 107.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 4.7 33.0%  
FIIs % 7.6 7.5 101.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 19.0 89.5%  
Shareholders   20,968 23,730 88.4%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   DR. DATSONS LABS  STRIDES SHASUN LTD  J.B.CHEMICALS  JUBILANT LIFE SCIENCES  BIOCON LTD  

Compare AJANTA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Aug 18, 2017 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 5-YR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS